Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (178)	12/10/1998 10:21:00 AM
From: scaram(o)uche	Respond to of 1475

Imutran presentation, today 4:10 p.m. (Boston) (the T Cell Sciences presentation is also relevant, as Novartis funds the xeno work for their complement inhibitors. They're now Avant Pharma, or something like that, having merged with VRII) 4:10 Elective Complement Depletion and Xenotransplantation Richard A. Harrison, Ph.D., Head of Complement Unit, Imutran Ltd., United Kingdom At the time of xenotransplantation the recipient experiences a massive complement "insult," triggered by high levels of naturally-occurring xenoreactive antibodies. While the transplanted xeno-organ is protected from hyperacute rejection (HAR) by human complement regulatory transgenes (e.g. hDAF), additional long-term benefit might accrue from elective depletion of complement activity prior to the xenotransplantation procedure. Progress in developing a reagent designed to achieve this will be reported. 4:40 Close of Day One

To: scaram(o)uche who wrote (178)	12/10/1998 10:23:00 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1475

The BTRN presentation, about four hours from now....... 2:40 Direct Approaches for the Induction of Transplantation Tolerance for Xenotransplantation Julia L. Greenstein, Ph.D. Success in the use of human organ transplantation has led to a critical shortage of organs. Use of animal organs offers the hope of addressing this need. Tolerance induction may be essential for successful clinical use of animal organs. Tolerance to xenogeneic cells or solid organs can be induced by using multiple approaches. Specific tolerance can be induced by establishing swine-into-primate bone marrow chimerism, by gene therapy utilizing SLA-DR containing retroviral vector transduction of autologous bone marrow and in a murine model by swine thymus transplantation.